CN Mobile Logo

Search form


US TOO! Surveys Prostate Ca Patients

US TOO! Surveys Prostate Ca Patients

NEW YORK-Although 90% of prostate cancer patients in a Harris poll cited delay of disease progression as a key benefit they seek from a therapy, only one third of physicians said they would be very likely to recommend complete hormonal therapy (CHT) (an oral antian-drogen drug plus castration therapy) for all of their stage D patients. Nearly all physicians said they discuss CHT with patients, but more than 50% of patients said it had not been presented as a treatment option. The poll was sponsored by the advocacy group US TOO! and funded by Schering Oncology/Biotech.

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.